Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

View
Open
Phase
Accrual
14%
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Status Notes
Active effective 09/19/2022
Research Committee(s)
Genitourinary Cancer
Activated
09-19-2022
ClinicalTrials.gov Registry Number
NCT05411081
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S2108CD

A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
Status Notes
This study will be permanently closed to new patient accrual, effective November 22, 2024, at 12:00 p.m. Pacific Time.
Research Committee(s)
Cancer Care Delivery
Activated
08-22-2022
ClinicalTrials.gov Registry Number
NCT # 05455606
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status Notes
Closed 6/27/2023
Research Committee(s)
LungMAP
Activated
07-25-2022
Closed
06-27-2023
ClinicalTrials.gov Registry Number
05364645
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status Notes
Activation Date: 06/06/2022
Research Committee(s)
Gastrointestinal Cancer
Activated
06-06-2022
ClinicalTrials.gov Registry Number
NCT05308446
Closed
Phase
Accrual
17%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status Notes
S1800D is permanently closed to accrual, effective March 10, 2023. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Closed
03-10-2023
Open
Phase
Accrual
34%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
Accrual
36%
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S2011

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Status Notes
The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
Closed
11-15-2023
ClinicalTrials.gov Registry Number
04871529
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1934

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
S1934 is permanently closed effective 3/1/2023.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
Closed
03-01-2023
ClinicalTrials.gov Registry Number
04989283
Open
Phase
Accrual
58%
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
Effective on 11/15/24 with Revision #6, Cohort 1 is permanently closed to accrual and Cohort 2 is open to enrollment.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Open
Phase
Accrual
98%
SWOG Clinical Trial Number
S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
This study will be permanently closed to new patient and caregiver accrual, effective December 16, 2024, at 12:00 p.m. Pacific Time.
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
10%
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Status Notes
Re-Activation - Effective (2/15/2024)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021
Open
Phase
Accrual
29%
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time

Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Open
Phase
Accrual
33%
SWOG Clinical Trial Number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Status Notes
Arm 2 will be Permanently Closed to Accrual and Arms 1 & 3 will be Reopened to Accrual as of 02/15/2024, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Open
Phase
Accrual
57%
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Status Notes
Activation - Effective 12/15/20, 12:00 PM Pacific Time

All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
Research Committee(s)
Breast Cancer
Activated
12-15-2020
ClinicalTrials.gov Registry Number
04647916
Open
Phase
Accrual
49%
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Open
Phase
Accrual
67%
SWOG Clinical Trial Number
S2001

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
33%
SWOG Clinical Trial Number
S1931

Phase III trial of Nivolumab and Ipilimumab with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Status Notes
Active effective 11/16/2020
Research Committee(s)
Genitourinary Cancer
Activated
11-16-2020
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Status Notes
Permanent Closure to Accrual, Effective June 18, 2024, at 3:00 PM Eastern Time.
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013